Effective November 24, 2014 Morgan Lewis & Bockius LLP and Bingham McCutchen LLP have concluded a transaction. Visitors seeking information on this page should visit the corresponding page on the Morgan Lewis & Bockius LLP website.

Bingham

Bingham
  1.  
  2. Save to My View (130)

For more information

  1. John Concannon
    1. John J. Concannon III
    2. Partner
    3. T +1.617.951.8874
  2. Joshua Dalton
    1. Joshua M. Dalton
    2. Partner
    3. T +1.617.951.8284
  3. Mark Hayman
    1. Mark L. Hayman, Ph.D.
    2. Partner
    3. T +1.617.951.8440

Bingham Enhances Life Sciences Patent Prosecution Capabilities

Mark Hayman, Ph.D., Joins as Partner, Adds Patent-Focused Life Sciences Practice

BOSTON (June 24, 2014) – Bingham McCutchen LLP has added Mark Hayman as a partner in its Boston office, enhancing the firm’s life sciences and patent counseling platforms.

Hayman joins Bingham’s Corporate Practice Group from the Boston office of Cooley LLP. His team focuses on patent counseling, procurement and licensing in the life sciences sector and has extensive experience in building patent portfolios to optimize product exclusivity positions.

“With the continued growth of the life sciences industry, Mark’s arrival at Bingham underscores our commitment to providing clients with comprehensive leading services in this sector,” said Jack Concannon, a Boston-based partner and co-leader of Bingham’s life sciences practice, noting that Hayman and his team will provide strategic benefit for clients in Boston and other key technology markets including California, New York and Washington, D.C.

Bingham’s life sciences practice represents numerous biotechnology, medical device, pharmaceutical, diagnostics and healthcare services companies in a wide range of activities from transactions to patent prosecution and litigation. The group also represents investment banks, venture capitalists, and other debt and equity providers investing in the life sciences sector. Clients include a broad spectrum of participants in life sciences matters, ranging in size from publicly held Fortune 500 companies to closely held businesses.

“Mark and his team not only allow us to deepen our ties to the Boston-area life sciences community, but they also represent an expansion of our patent prosecution practice that will benefit our clients firmwide,” added Josh Dalton, co-managing partner of Bingham’s Boston office and a member of the firm’s Intellectual Property Group. 

Bingham’s commitment to the life sciences sector, the depth of its legal talent, and the opportunity to help enhance the firm’s offerings to the pharmaceutical and biotech industries in patent prosecution and counseling attracted Hayman to the firm.
“We are excited to join Bingham, and we look forward to combining our unique, practical and creative patent practice with the Bingham platform,” Hayman said. “This is a great opportunity for our clients and our team.”

Hayman and his team have deep experience in a wide range of technologies, including biologics, pharmaceuticals, microbial engineering, enzyme engineering, molecular diagnostics, nucleic acid sequencing technologies, nutraceuticals, wound care, and nucleic acid- and peptide-based therapeutics. Hayman is admitted to practice in Massachusetts, Maryland and the District of Columbia. He also is registered to practice before the U.S. Patent and Trademark Office.

A graduate of the University of Pittsburgh School of Law, Hayman earned his bachelor’s degree in biology from the State University of New York at Potsdam and his Ph.D. in microbiology from the State University of New York at Buffalo.

Back to Top

Legal insight. Business instinct. Global intelligence. ®